Aortic valve Myocardial Infarction Preserved Ejection Fraction 
Heart BMJ
MARCH 26, 2025
Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. Among patients with myocardial infarction, a 1-SD increase in pulse pressure was associated with a 1.60-fold
Heart BMJ
MARCH 26, 2025
Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 However, mortality rate is greater in HF cases developing >3 days following MI compared with less than or equal to 3 days after MI.
Open Heart
JANUARY 8, 2024
Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aortic valve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
DAIC
FEBRUARY 29, 2024
ET Main Tent (Hall B1) - A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial - Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial - CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients (..)
Cardiology Update
APRIL 9, 2024
EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR).
Expert insights. Personalized for you.
52 
Let's personalize your content